Sumitomo Pharma Oncology
Sumitomo Pharma Oncology is a novel cancer therapeutics developer. Their research includes survival mechanisms and novel protein interactions. They are committed to pursuing a diverse and purposeful pipeline that investigates drivers of treatment resistance and tumor progression.
Industries
Nr. of Employees
medium (51-250)
Patents
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US-12077554-B2
View DetailsCompositions comprising PKM2 modulators and methods of treatment using the same
US-11712433-B2
View DetailsCDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US-11530231-B2
View Details
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US-12077554-B2
View DetailsCompositions comprising PKM2 modulators and methods of treatment using the same
US-11712433-B2
View DetailsCDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US-11530231-B2
View DetailsProducts
Nuvisertib (TP-3654)
A therapeutic agent under development for the treatment of myelofibrosis, designated for expedited review by the FDA.
Universal Influenza Vaccine Candidate (fH1/DSP-0546LP)
A next-generation vaccine candidate designed to provide broad protection against various influenza virus strains.
DrugOME
A data-driven platform that analyzes diverse datasets to support drug discovery and development decisions.
Digital Innovation System
A digital platform that develops tailored applications and automation solutions to improve operational efficiency across business units.
In Silico Drug Discovery Technology
Computational methods used to identify drug targets and design candidate molecules using large-scale data analysis and molecular simulations.
Regenerative Medicine and Cell Therapy Products
Therapeutic products derived from allogenic iPS cells aimed at treating diseases through regenerative approaches.
Nuvisertib (TP-3654)
A therapeutic agent under development for the treatment of myelofibrosis, designated for expedited review by the FDA.
Universal Influenza Vaccine Candidate (fH1/DSP-0546LP)
A next-generation vaccine candidate designed to provide broad protection against various influenza virus strains.
DrugOME
A data-driven platform that analyzes diverse datasets to support drug discovery and development decisions.
Digital Innovation System
A digital platform that develops tailored applications and automation solutions to improve operational efficiency across business units.
In Silico Drug Discovery Technology
Computational methods used to identify drug targets and design candidate molecules using large-scale data analysis and molecular simulations.
Regenerative Medicine and Cell Therapy Products
Therapeutic products derived from allogenic iPS cells aimed at treating diseases through regenerative approaches.